Bildnachweis: Zahfran – stock.adobe.com, LIPH, stock3.com, Phoenix AI Photo – stock.adobe.com.
Leo International Precision Health AG (LIPH) is an investment holding company (WKN: 549060; ticker: LEOW) that has been listed on the stock exchange since December 2025 and is building a portfolio of AI-driven precision health companies in biotech, medtech, healthtech, and healthcare services. LIPH currently has six majority shareholdings.
Plattform Life Sciences: Prof. Dr Joshua Lo, you took over as CEO of LIPH AG in 2025. What strategic decisions have you made since then?
Prof. Dr Lo: When I took over in 2025, the initial focus was on establishing a clear strategic direction. We have developed LIPH AG from a broadly based holding company into a precision health platform that actively supports its investments at the operational level. This involved three key strategic decisions first, a consistent focus on majority investments in technologically innovative life sciences companies; second, the systematic anchoring of AI and data-driven approaches as a synergistic element of the portfolio; and third, the establishment of synergistic operational structures along key value creation stages such as diagnostics, clinical validation, and market access. The aim of this realignment was not to view the individual investments in isolation, but to specifically increase their technological and operational connectivity through cross-pollination, restructuring, and synergy effects. In this way, we are creating a base not only for financing innovations, but also for actively managing their development, scalability, and subsequent commercialization.
You implemented the first batch oft he portfolio core in December 2025. Which companies are included?
As part of a capital increase through contributions in kind, the publicly listed holding company acquired six majority shareholdings, which are active in key areas of precision medicine and complement each other technologically and operationally. These include, among others, Dr Pain, headquartered in Hong Kong, who operates 24 pain rehabilitation clinics across Taiwan, Hong Kong, and China; Pathomics Health in Singapore, who specializes in precision diagnostics and digital preventive health innovation; and UHO Wellness (Immune Anima Inc.) in Taiwan, who focuses on nutraceuticals and health-management products.
What criteria do you consider when making these investment decisions, and how does your investment strategy differ from that of traditional life sciences investors?
We invest strategically and globally, with a focus on acquiring majority stakes. We focus on companies whose innovative technologies, products, and services are based on data or AI-driven approaches and synergies within the portfolio. Within this framework, we select our investments based on scientific validity, regulatory maturity, data integrity, and potential for recurring revenues. This includes robust business models with transparent, scalable monetization paths, such as regulated diagnostic services, licensing models, or recurring service revenues. The difference between us and traditional financial investors ist hat rather than focusing on the isolated value enhancement of individual assets, we concentrate on their development within an integrated structure.
What specific role does LIPH play in the further development of portfolio companies after its initial investment?
Beyond the capital aspect, we see ourselves as active development partners. We support our portfolio companies in establishing common technological foundations, accessing international networks, and addressing regulatory and clinical issues. In addition, cross-marketing and brand integration accelerate market penetration. We also pool resources where economies of scale can be realized, for example in data infrastructure, validation processes, or business development activities. This approach enables individual companies to focus more on their core competencies, while LIPH provides overarching structures.
What is LIPH’s vision for the coming years, and how do you plan to execute on your growth strategy?
LIPH’s vision is to build a leading global platform for AI-driven precision healthcare, connecting innovation ecosystems across Asia, Europe, and other key markets. We pursue disciplined growth supported by a continuous and structured deal funnel. Our team consistently screens and evaluates companies with strong technological differentiation, scalable and revenue-generating business models and clear value-creation potential. LIPH’s investment approach is focuses on AI-driven healthcare assets where we can unlock measurable operational and data-based synergies, translating into sustainable long-term shareholder value.
Prof. Dr Joshua Lo, thank you very much for these interesting insights.
The interview was conducted by Urs Moesenfechtel.
The investor profile of Leo International Precision Health AG can be found on page 72.
Autor/Autorin
Urs Moesenfechtel, M.A., ist Redaktionsleiter der Plattform Life Sciences und gehört zum Redaktionsteam der Kapitalmarkt-Plattform GoingPublic (GoingPublic, HV Magazin, www.goingpublic.de). Urs beschäftigt sich seit vielen Jahren mit den Themenfeldern Biotechnologie und Bioökonomie und war u.a. bereits als Wissenschaftsredakteur für mehrere Forschungseinrichtungen tätig.
Themenverwandte Artikel:
„Sie fallen durch alle klassischen Raster – und genau dort sehen wir unsere Rolle.“
„Der zweite Fonds ist keine Neuausrichtung, sondern die Skalierung eines bewährten Modells.“
„In Leipzig findet man, was andernorts leicht übersehen wird“
Organoids and organs on chips – an emerging biotech/pharma business